飙涨148%!东阳光药大突破,39款1类新药来势汹汹,12款新药上市可期

米内网
Sep 16

精彩内容今年以来,东阳光药产品研发持续推进:2款1类新药首次获批上市,2款生物类似药首次提交NDA,3款1类新药首次获批临床等。东阳光药坚持“创新”和“国际化”双引擎驱动,目前公司有57款新药(39款1类新药)在国内处于申请临床及以上阶段,其中有12款新药已提交NDA或处于III期临床(含II/III期),上市可期。大丰收!2款1类新药获批,胰岛素收入大涨8月7日,东阳光药吸收合并港股上市子公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10